Skip to content

Study · Animal study (in vivo) · beagle dogs · 2003

6 results

The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

Agersø H, Koechling W, Knutsson M, Hjortkjaer R, Karlsson MO

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences1 Nov 2003Cited by 12 (Europe PMC)

PMID14592699 (opens in a new tab)DOI10.1016/j.ejps.2003.08.001 (opens in a new tab)PepBankPUB-14592699
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, degarelix concentrations followed a two-compartment model with fast and slow first-order absorption inputs.

    In plain wordsIn dogs, degarelix showed fast initial absorption and prolonged slow absorption.

    Peptide
    Degarelix
    Outcome
    Not applicableAbsorption model
    Study

    beagle dogsn = 27

    male beagle dogs
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · subcutaneous or intramuscularAs given in this study (beagle dogs).

    Source sentences

    Summary
    After s.c. and i.m. administration of degarelix, the plasma concentration versus time profile was best described by applying a two-compartment model, with two input functions: a fast first-order input function to describe the rapid initial increase in the plasma concentration levels, and a slow firs…
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, intramuscular degarelix reached a mean maximum concentration of 64 versus 31 ng/ml after subcutaneous dosing.

    In plain wordsIn dogs, intramuscular degarelix reached higher peak concentrations than subcutaneous degarelix.

    Peptide
    Degarelix
    Outcome
    IncreaseMaximum concentration
    Study

    beagle dogsn: not reported in source

    male beagle dogs
    Comparator
    subcutaneous administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · intramuscular versus subcutaneousAs given in this study (beagle dogs).

    Measurements

    Maximum concentration
    64 ng/ml
    intramuscular
    Maximum concentration
    31 ng/ml
    subcutaneous

    Source sentences

    Summary
    Intra-muscular as opposed to s.c. administration led to a more rapid absorption of degarelix, reaching a mean maximum concentration of 64 and 31 ng/ml roughly 2.0 and 3.7 h after administration, respectively.
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, intramuscular degarelix reached peak concentration at roughly 2.0 versus 3.7 h after subcutaneous dosing.

    In plain wordsIn dogs, intramuscular degarelix reached peak concentration sooner than subcutaneous degarelix.

    Peptide
    Degarelix
    Outcome
    DecreaseTime to maximum concentration
    Study

    beagle dogsn: not reported in source

    male beagle dogs
    Comparator
    subcutaneous administration
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · intramuscular versus subcutaneousAs given in this study (beagle dogs).

    Measurements

    Time to maximum concentration
    2 h
    intramuscular
    Time to maximum concentration
    3.7 h
    subcutaneous

    Source sentences

    Summary
    Intra-muscular as opposed to s.c. administration led to a more rapid absorption of degarelix, reaching a mean maximum concentration of 64 and 31 ng/ml roughly 2.0 and 3.7 h after administration, respectively.
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, degarelix had a slow absorption half-life of 268 h, approximately 11 days.

    In plain wordsIn dogs, the slow absorption half-life of degarelix was approximately 11 days.

    Peptide
    Degarelix
    Outcome
    Not applicableSlow absorption half-life
    Study

    beagle dogsn: not reported in source

    male beagle dogs
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · subcutaneous or intramuscularAs given in this study (beagle dogs).

    Measurements

    Slow absorption half-life
    268 h
    reported result

    Source sentences

    Summary
    The slow absorption half-life was found to be 268 h ( approximately 11 days).
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, increasing degarelix solution concentration from 1.25 to 40 mg/ml reduced the absorbed fraction by approximately 50%.

    In plain wordsIn dogs, more concentrated degarelix solution reduced the absorbed fraction compared with the lower concentration.

    Peptide
    Degarelix
    Outcome
    DecreaseAbsorbed fraction by solution concentration
    Study

    beagle dogsn: not reported in source

    male beagle dogs
    Comparator
    1.25 mg/ml dosing solution
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · subcutaneous or intramuscularAs given in this study (beagle dogs).

    Measurements

    Absorbed fraction reduction
    ≈ 50%
    1.25 to 40 mg/ml

    Source sentences

    Summary
    The present analysis suggested that the absorbed fraction was reduced by approximately 50% when the concentration in dosing solution was increased from 1.25 to 40 mg/ml.
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In beagle dogs, higher degarelix solution concentrations slowed the initial absorption component.

    In plain wordsIn dogs, higher degarelix concentrations slowed initial absorption compared with lower concentrations.

    Peptide
    Degarelix
    Outcome
    DecreaseInitial absorption rate
    Study

    beagle dogsn: not reported in source

    male beagle dogs
    Comparator
    lower dosing solution concentrations
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.25-1.5 mg/kg · subcutaneous or intramuscularAs given in this study (beagle dogs).

    Source sentences

    Summary
    The rate of the initial absorption component was also dependent on the concentration in the dosing solution, with slower absorption at higher concentrations.
    3 context sentences
    Summary · context
    The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administration to male beagle dogs, and to determine the influence of the different dosing conditions on the absorption profile of degarelix.
    Summary · context
    Degarelix was administered to 27 dogs and plasma concentrations were measured.
    Summary · context
    The dosing conditions varied with respect to route (s.c. or i.m.), dose (0.25-1.5 mg/kg), solution strength (1.25-40 mg/ml) and volume administered (0.15-2.9 ml).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.